Bank of Marin Increases Holdings in Johnson & Johnson (NYSE:JNJ)

Bank of Marin increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 60.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,815 shares of the company’s stock after buying an additional 1,066 shares during the quarter. Bank of Marin’s holdings in Johnson & Johnson were worth $407,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. IFS Advisors LLC increased its stake in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the last quarter. RPg Family Wealth Advisory LLC acquired a new stake in Johnson & Johnson during the third quarter worth $35,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth $32,000. Activest Wealth Management acquired a new stake in Johnson & Johnson during the third quarter worth $40,000. Finally, NewSquare Capital LLC increased its stake in Johnson & Johnson by 145.8% during the fourth quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock worth $42,000 after acquiring an additional 172 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Up 0.9 %

JNJ opened at $164.24 on Wednesday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock has a market capitalization of $395.80 billion, a price-to-earnings ratio of 24.70, a PEG ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The business has a fifty day moving average price of $155.73 and a 200 day moving average price of $156.25.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.29 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Wells Fargo & Company cut their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Morgan Stanley cut their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Argus raised Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Stifel Nicolaus dropped their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.